Renaissance Technologies Cut Its Enanta Pharmaceuticals (ENTA) Stake; Synacor (SYNC) Shorts Up By 5.45%

July 17, 2017 - By Marguerite Chambers

Renaissance Technologies Llc decreased Enanta Pharmaceuticals Inc (ENTA) stake by 18.05% reported in 2016Q4 SEC filing. Renaissance Technologies Llc sold 126,629 shares as Enanta Pharmaceuticals Inc (ENTA)’s stock rose 11.35%. The Renaissance Technologies Llc holds 574,771 shares with $19.26 million value, down from 701,400 last quarter. Enanta Pharmaceuticals Inc now has $703.73M valuation. The stock declined 3.18% or $1.19 reaching $36.08 per share. About 111,801 shares traded. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has risen 40.91% since July 17, 2016 and is uptrending. It has outperformed by 24.21% the S&P500.

Synacor Incorporated (NASDAQ:SYNC) had an increase of 5.45% in short interest. SYNC’s SI was 473,700 shares in July as released by FINRA. Its up 5.45% from 449,200 shares previously. With 109,600 avg volume, 4 days are for Synacor Incorporated (NASDAQ:SYNC)’s short sellers to cover SYNC’s short positions. The SI to Synacor Incorporated’s float is 2.02%. About 142,533 shares traded or 3.72% up from the average. Synacor Inc (NASDAQ:SYNC) has risen 15.89% since July 17, 2016 and is uptrending. It has underperformed by 0.81% the S&P500.

Analysts await Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to report earnings on August, 14. They expect $-0.49 earnings per share, down 716.67% or $0.43 from last year’s $-0.06 per share. After $-0.28 actual earnings per share reported by Enanta Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 75.00% negative EPS growth.

Investors sentiment decreased to 1.47 in Q4 2016. Its down 0.06, from 1.53 in 2016Q3. It is negative, as 13 investors sold ENTA shares while 36 reduced holdings. 23 funds opened positions while 49 raised stakes. 12.65 million shares or 0.84% less from 12.75 million shares in 2016Q3 were reported. Eqis Management reported 35,326 shares stake. Granahan Investment Mgmt Ma holds 0.57% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 496,025 shares. Arizona State Retirement System owns 7,200 shares. Moreover, Renaissance Tech Limited Liability Corporation has 0.03% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Clarivest Asset Ltd holds 0.01% or 13,300 shares in its portfolio. Matarin Cap Mgmt Limited Company has 0% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 257,268 shares. Strs Ohio holds 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 23,000 shares. Wellington Mgmt Group Inc Ltd Liability Partnership accumulated 42,878 shares or 0% of the stock. Krensavage Asset Management Ltd Llc holds 1.06 million shares or 12.68% of its portfolio. Federated Pa holds 460 shares or 0% of its portfolio. Tudor Inv Corp Et Al holds 0.01% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) or 15,470 shares. Oakworth Cap Inc holds 263 shares. Blackrock Llc has invested 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Great West Life Assurance Can, Manitoba – Canada-based fund reported 17,185 shares. Hays Advisory Ltd Llc owns 0.87% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 116,939 shares.

Renaissance Technologies Llc increased Select Sector Spdr Tr (XLU) stake by 126,200 shares to 147,400 valued at $7.16M in 2016Q4. It also upped American Elec Pwr Inc (NYSE:AEP) stake by 558,392 shares and now owns 3.89 million shares. Summit Financial Group Inc (NASDAQ:SMMF) was raised too.

Among 4 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Enanta Pharmaceuticals Inc had 12 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Underweight” rating by Barclays Capital given on Friday, October 23. As per Tuesday, August 9, the company rating was maintained by JP Morgan. The firm has “Buy” rating given on Friday, August 7 by Zacks. The firm earned “Mkt Outperform” rating on Friday, October 23 by JMP Securities. The stock has “Buy” rating by TheStreet on Saturday, August 8. The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has “Market Outperform” rating given on Tuesday, July 11 by JMP Securities. The firm earned “Market Perform” rating on Thursday, April 28 by JMP Securities.

Synacor, Inc. is a technology development, multiplatform services and revenue partner for video, Internet and communications providers, device manufacturers and enterprises. The company has market cap of $142.55 million. The Firm enables its clients to provide their clients engaging, multiscreen experiences with products that require scale, actionable data and implementation. It currently has negative earnings. Through its Managed Portals and Advertising solutions, the Company enables its clients to earn revenue by monetizing media among their consumers.

Investors sentiment increased to 1.75 in Q4 2016. Its up 0.11, from 1.64 in 2016Q3. It improved, as 6 investors sold Synacor Inc shares while 6 reduced holdings. 8 funds opened positions while 13 raised stakes. 5.10 million shares or 28.14% more from 3.98 million shares in 2016Q3 were reported. Two Sigma Limited Liability invested in 12,194 shares or 0.01% of the stock. Vanguard Grp invested in 0% or 654,425 shares. Tower Research Cap Lc (Trc) reported 4,105 shares. Bridgeway Mngmt holds 0.01% or 251,800 shares. New Jersey Better Educational Savings Tru reported 140,000 shares. Globeflex Capital Limited Partnership invested 0% in Synacor Inc (NASDAQ:SYNC). Geode Cap Management Ltd Liability Corporation stated it has 129,572 shares or 0% of all its holdings. California Pub Employees Retirement Sys reported 13,700 shares or 0% of all its holdings. Bankshares Of Mellon Corporation stated it has 0% of its portfolio in Synacor Inc (NASDAQ:SYNC). Wellington Mngmt Gp Limited Liability Partnership owns 748,200 shares or 0% of their US portfolio. 32,000 were accumulated by Art Advisors Ltd Co. Manufacturers Life Ins Communications The, a Ontario – Canada-based fund reported 186 shares. Acadian Asset Lc reported 86,196 shares or 0% of all its holdings. Goldman Sachs Group Incorporated has invested 0% in Synacor Inc (NASDAQ:SYNC). Moreover, Dimensional Fund Advsrs Lp has 0% invested in Synacor Inc (NASDAQ:SYNC) for 50,965 shares.

Among 4 analysts covering Synacor (NASDAQ:SYNC), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Synacor had 4 analyst reports since October 18, 2016 according to SRatingsIntel. The firm has “Buy” rating by Rosenblatt given on Monday, June 12. Lake Street initiated the stock with “Buy” rating in Tuesday, February 14 report. The rating was initiated by Ladenburg Thalmann on Tuesday, October 18 with “Buy”.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.